

## DAFTAR PUSTAKA

1. Cantor LB, Rapuano CJ, Cioffi GA. Thyroid Eye Disease. In: Orbit, Eyelid and Lacrimal System. San Fransisco: American Academy of Ophthalmology; 2019. p. 41–6.
2. Joseph S, Douglas R. Thyroid Eye Disease: a Comprehensive Review. In: Orbital Inflammatory Diseases and Their Differential Diagnosis. 2015. p. 73–83.
3. Soebagjo HD. Thyroid Associated Orbitopathy. *Global Persada Pers*. 2015. 11–63 p.
4. Bartalena L. Prevention of Grave's Ophthalmopathy. In: Best Practice and Research Clinical Edocrinology & Metabolism. Elsevier; 2011. p. 371–7.
5. Barrio-Barrio J, Sabater AL, Bonet-Farriol E, Velázquez-Villoria Á, Galofré JC. Graves' ophthalmopathy: VISA versus EUGOGO classification, assessment, and management. *J Ophthalmol*. 2015;2015.
6. Verity DH, Rose GE. Acute thyroid eye disease ( TED ): Principles of medical and surgical management. *Eye* [Internet]. 2013;27(3):308–19. Available from: <http://dx.doi.org/10.1038/eye.2012.284>
7. Bhatt R, Nelson CC, Douglas RS. Thyroid-associated orbitopathy: Current insights into the pathophysiology, immunology and management. *Saudi J Ophthalmol* [Internet]. 2011;25(1):15–20. Available from: <http://dx.doi.org/10.1016/j.sjopt.2010.11.002>
8. Fajar J, Hidayah C, Zaini L. Korelasi Derajat Graves' Ophthalmopathy dengan Durasi Menderita Hipertiroid. In: *CDK-228 Volume 42 No 5*. 2015. p. 327–9.
9. Perros P, Hegedüs L, Bartalena L, Marcocci C, Kahaly GJ, Baldeschi L, et al. Graves' orbitopathy as a rare disease in Europe : a European Group on Graves' Orbitopathy ( EUGOGO ) position statement. *Orphanet J Rare Dis*. 2017;12(72):1–6.
10. Ackuaku-dogbe EM, Akpalu J, Abaidoo B. Epidemiology and Clinical Features of Thyroid-associated Orbitopathy in Accra. *Middle East Afr J Ophthalmol*. 2018;24(4):183–9.
11. Lim SL, Keat A, Lim E, Mumtaz M, Hussein E, Mohamad W, et al. Prevalence, Risk Factors, and Clinical Features of Thyroid-Associated Ophthalmopathy in Multiethnic Malaysian Patients with Graves' Disease. *THYROID*. 2008;18(12):1297–301.
12. Subekti I. Oftalmopati Graves : Perbandingan Karakteristik Klinis, Kadar Hormon, dan Kadar Antibodi Reseptor TSH. *eJKI*. 2018;6(1):1–6.
13. Sirmalinda. Hubungan antara Tekanan Intraokular Upgaze dengan Derajat Beratnya Oftalmopati pada Penyakit Graves. Thesis. Universitas Andalas; 2012. 1–65 p.
14. Rahayu I. Hubungan antara Lama Pemakaian Propiltiourasil dengan Perubahan Derajat Oftalmopati Graves pada Penyakit Graves. Universitas Andalas; 2015. 9–66 p.
15. Kim JM, LaBree L, Levin L, Feldon SE. The relation of Graves' ophthalmopathy to circulating thyroid hormone status. *Br J Ophthalmol*. 2004;88(1):72–4.
16. Kahaly G. Diagnosis and Endocrine Management of Graves' Disease. In: *Thyroid Eye Disease*. New York: Springer; 2015. p. 1–7.
17. Many MC, Costagliola S, Detrait M, Deneff JF, Vassart G, Ludgate M. Development of an animal model of autoimmune thyroid eye disease. *J Immunol*. 1999;162(8):4966–74.
18. Subekti I, Boedisantoso A, Moeloek ND, Waspadji S, Mansyur M. Association of TSH receptor antibody, thyroid stimulating antibody, and thyroid blocking antibody with clinical activity score and degree of severity of Graves ophthalmopathy. *Acta Med Indones*. 2012;44(2):114–21.

19. Gharib S, Moazezi Z, Bayani MA. Prevalence and severity of ocular involvement in Graves' disease according to sex and age: A clinical study from Babol, Iran. *Casp J Intern Med.* 2018;9(2):178–83.
20. Nassr MA, Morris CL, Netland PA, Karcioğlu ZA. Intraocular pressure change in orbital disease. *Surv Ophthalmol.* 2009;54(5):519–44.
21. Khong JJ, McNab AA, Ebeling PR, Craig JE, Selva D. Pathogenesis of thyroid eye disease: Review and update on molecular mechanisms. *Br J Ophthalmol.* 2016;100(1):142–50.
22. Meirovitch SB, Leibovitch I, Kesler A, Varssano D, Rosenblatt A, Neuderfer M. Retina and nerve fiber layer thickness in eyes with thyroid-associated ophthalmopathy. *Isr Med Assoc J.* 2017;19(5):277–81.
23. Blandford AD, Zhang D, Chundury R V, Julian D, Foundation CC. Dysthyroid optic neuropathy: update on pathogenesis, diagnosis, and management. *Expert Rev Ophthalmol.* 2018;12(2):111–21.
24. Mugdha K, Kaur A, Sinha N, Saxena S. Evaluation of retinal nerve fiber layer thickness profile in thyroid ophthalmopathy without optic nerve dysfunction. *Int J Ophthalmol.* 2016;9(11):1634–7.
25. Wei YH, Chi MC, Liao SL. Predictability of visual function and nerve fiber layer thickness by cross-sectional areas of extraocular muscles in graves ophthalmopathy. *Am J Ophthalmol* [Internet]. 2011;151(5):901–906.e1. Available from: <http://dx.doi.org/10.1016/j.ajo.2010.11.001>
26. Forte R, Bonavolontà P, Vassallo P. Evaluation of retinal nerve fiber layer with optic nerve tracking optical coherence tomography in thyroid-associated orbitopathy. *Ophthalmologica.* 2010;224(2):116–21.
27. Danesh-Meyer H V, Carroll SC, Foroozan R, Savino PJ, Fan J, Jiang Y, et al. Relationship between retinal nerve fiber layer and visual field sensitivity as measured by optical coherence tomography in chiasmal compression. *Investig Ophthalmol Vis Sci.* 2006;47(11):4827–35.
28. Choi CJ, Oropesa S, Callahan AB, Glass LR, Teo L, Cestari DM, et al. Patterns of visual field changes in thyroid eye disease. *Orbit (London)* [Internet]. 2017;36(4):201–7. Available from: <http://dx.doi.org/10.1080/01676830.2017.1314510>
29. Dickinson AJ, Perros P. Controversies in the clinical evaluation of active thyroid-associated orbitopathy: Use of a detailed protocol with comparative photographs for objective assessment. *Clin Endocrinol (Oxf).* 2001;55(3):283–303.
30. Labonia AF, Carnovale-Scalzo G, Paola A, De'Morelli G, Scorcina V, Bruzzichessi D, et al. Subclinical visual field alterations are commonly present in patients with Graves' Orbitopathy and are mainly related to the clinical activity of the disease. *Exp Clin Endocrinol Diabetes.* 2008;116(6):347–51.
31. Levin LA. Chapter 21 Physiology of the Optic Nerve. *Duane's Clin Ophthalmol.* 2017;2:1–27.
32. U S, W H. Functional Anatomy of the Human Visual Pathway. In: *Clinical NeuroOphthalmology: A Practical Guide.* 2007. p. 19–28.
33. Prasad S, Galetta SL. Anatomy and physiology of the afferent visual system. 1st ed. Vol. 102, *Handbook of Clinical Neurology.* Elsevier B.V.; 2011. 3–19 p.
34. Eckstein A, Quadbeck B, Mueller G, Rettenmeier AW, Hoermann R, Mann K, et al. Impact of smoking on the response to treatment of thyroid associated ophthalmopathy. *Br J Ophthalmol.* 2003;87(6):773–6.
35. Sadeghi-Tari A, Jamshidian-Tehrani M, Nabavi A, Sharif-Kashani S, Elhami E, Hassanpour N, et al. Effect of smoking on retrobulbar blood flow in thyroid eye disease. *Eye.* 2016;30(12):1573–8.
36. Thornton J, Kelly SP, Harrison RA, Edwards R. Cigarette smoking and thyroid eye disease: A systematic review. *Eye.* 2007;21(9):1135–45.

37. Åsman P. Ophthalmological evaluation in thyroid-associated ophthalmopathy. Vol. 81, *Acta Ophthalmologica Scandinavica*. 2003. p. 437–48.
38. Wall JR, Lahooti H. Pathogenesis of thyroid eye disease--does autoimmunity against the TSH receptor explain all cases? *Endokrynol Pol*. 2010;61(2):222–7.
39. Saraci G, Treta A. Ocular Changes and Approaches of Ophthalmopathy in Graves Disease. *Medica*. 2011;6(2):146–52.
40. Şahlı E, Gündüz K. Thyroid-associated Ophthalmopathy. *Turkish J Ophthalmol*. 2017;47:94–105.
41. Mallika PS, Tan AK, Aziz S, Alwi SARS, Chong MS, Ms RV, et al. Thyroid Associated Ophthalmopathy - A Review. *Malaysian Fam Physician*. 2009;4(1):8–14.
42. Werner SC. Modification of the classification of the eye changes of Graves' disease: recommendations of the Ad Hoc Committee of the American Thyroid Association. Vol. 44, *The Journal of clinical endocrinology and metabolism*. 1977. p. 203–4.
43. Mourits MP, Koornneef L, Wiersinga WM, Prummel MF, Berghout A, van der Gaag R. Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach. *Br J Ophthalmol*. 1989 Aug;73(8):639–44.
44. Cantor LB, Rapuano CJ, Cioffi GA. Evaluation of Orbital Disorder. In: *Orbit, Eyelid and Lacrimal System*. San Fransisco: American Academy of Ophthalmology; 2015. p. 21–7.
45. Kanski J. *Kanski's Clinical Ophthalmology: A Systemic Approach*. Elsevier; 2015. 103–106 p.
46. Kwon H, Kim WG, Jang EK, Kim M, Park S, Jeon MJ, et al. Usefulness of Measuring Thyroid Stimulating Antibody at the Time of Antithyroid Drug Withdrawal for Predicting Relapse of Graves Disease. *Endocrinol Metab (Seoul, Korea)*. 2016 Jun;31(2):300–10.
47. Ludgate M, Baker G. Unlocking the immunological mechanisms of orbital inflammation in thyroid eye disease. *Clin Exp Immunol [Internet]*. 2002 Feb;127(2):193–8. Available from: <https://pubmed.ncbi.nlm.nih.gov/11876739>
48. Yang DD, Gonzalez MO, Durairaj VD. Medical management of thyroid eye disease. *Saudi J Ophthalmol Off J Saudi Ophthalmol Soc [Internet]*. 2010/10/26. 2011 Jan;25(1):3–13. Available from: <https://pubmed.ncbi.nlm.nih.gov/23960897>
49. Dong ZM, Wollstein G, Schuman JS. Clinical utility of optical coherence tomography in glaucoma. *Investig Ophthalmol Vis Sci*. 2016;57(9):556–67.
50. Nordmann J-P. *OCT & Optic Nerve*. Paris: Carl Zeiss Meditec; 2017. 42–130 p.
51. Mohammadi K, Bowd C, Weinreb RN, Medeiros FA, Sample PA, Zangwill LM. Retinal Nerve Fiber Layer Thickness Measurements With Scanning Laser Polarimetry Predict Glaucomatous Visual Field Loss. *Am J Ophthalmol*. 2006;142(4):576–82.
52. Bowd C, Weinreb RN, Williams JM, Zangwill LM. The Retinal Nerve Fiber Layer Thickness in Ocular Hypertensive, Normal, and Glaucomatous Eyes with Optical Coherence Tomography. *Arch Ophthalmol*. 2000;118(118):22–6.
53. Park K-A, Kim Y-D, Woo KI. Changes in optical coherence tomography measurements after orbital wall decompression in dysthyroid optic neuropathy. *Eye (Lond) [Internet]*. 2018/03/01. 2018 Jun;32(6):1123–9. Available from: <https://pubmed.ncbi.nlm.nih.gov/29491488>
54. Carl Zeiss Meditec I. *Cirrus HD-OCT : How to read the Cirrus reports*. Review Literature And Arts Of The Americas. California: Carl Zeiss Meditec; 2011. p. 1–13.
55. Heijl A, Patella V, Bengtsson B. *STATPAC Analysis Of Single Field*. In: *The Field Analyzer Primer : Effective Perimetry*. California: Carl Zeiss Meditec; 2012. p. 45–59.
56. Gupta A, Choudhry R, Tandon C. *Humphrey Field Analyzer*. In: *Step by Step*

- Visual Field Examination. New Delhi: Jaypee Brothers; 2007. p. 93–123.
57. Saeed P, Tavakoli Rad S, Bisschop PHLT. Dysthyroid Optic Neuropathy. *Ophthalm Plast Reconstr Surg*. 2018;34(4S Suppl 1):S60--S67.
  58. Baril C, Pouliot D, Molgat Y. Optic neuropathy in thyroid eye disease : results of the balanced decompression technique. *Can J Ophthalmol Can d'ophtalmologie* [Internet]. 2014;49(2):162–6. Available from: <http://dx.doi.org/10.1016/j.jcjo.2013.10.006>
  59. McKeag D, Lane C, Lazarus JH, Baldeschi L, Boboridis K, Dickinson AJ, et al. Clinical features of dysthyroid optic neuropathy: a European Group on Graves' Orbitopathy (EUGOGO) survey. *Br J Ophthalmol*. 2007 Apr;91(4):455–8.
  60. Neudorfer M, Blum S, Kesler A, Varssano D, Leibovitch I. Retinal and peripapillary nerve fiber layer thickness in eyes with thyroid-associated ophthalmopathy. *IOVS*. 2013;54(15):1436–41.
  61. Sayin O, Yeter V, Aritürk N. Optic Disc, Macula, and Retinal Nerve Fiber Layer Measurements Obtained by OCT in Thyroid-Associated Ophthalmopathy. *J Ophthalmol*. 2016;16:1–7.
  62. Freitag SK, Tanking T. A Nomenclature to Describe the Sequence of Visual Field Defects in Progressive Thyroid Eye Disease–Compressive Optic Neuropathy (An American Ophthalmological Society Thesis). *Am J Ophthalmol*. 2020;213:293–305.
  63. Ramakrishnan R, Mittal S, Ambatkar S, Kader MA. Retinal nerve fibre layer thickness measurements in normal Indian population by optical coherence tomography. *Indian J Ophthalmol*. 2006;54(1):11–5.

